How to Get Vyvanse in District of Columbia

What Vyvanse Is and Why DC Patients Seek It

Vyvanse is a prodrug stimulant manufactured by Takeda Pharmaceuticals. After oral ingestion, the body cleaves lisdexamfetamine into the active compound d-amphetamine in red blood cells, producing a slower, smoother onset than immediate-release amphetamine salts. The FDA approved Vyvanse for ADHD in children aged 6 and older in 2007 and for adults in 2008. A second FDA approval for moderate-to-severe binge eating disorder (BED) in adults followed in 2015, making Vyvanse the first and still the only FDA-approved pharmacotherapy for BED. Vyvanse prescribing information is available at the FDA's access data portal.

Why Patients in DC Are Looking for Access

Washington, DC's provider density is high compared with most of the country, yet psychiatry and ADHD-specialist wait times at academic medical centers such as MedStar Georgetown and George Washington University Hospital routinely run 6 to 14 weeks. That gap drives DC residents toward telehealth platforms that can see a new patient within 48 to 72 hours.

DC also has a disproportionately large federal-employee population covered by Federal Employee Health Benefits (FEHB) plans. Many FEHB formularies list Vyvanse as a Tier 3 specialty drug, meaning prior authorization is common even outside Medicaid. Knowing the exact documentation requirements before your first appointment saves days of back-and-forth.

DEA Schedule II Rules That Govern Every DC Prescription

Vyvanse is a DEA Schedule II controlled substance. That classification carries specific legal constraints that apply to every DC prescription, whether written by a psychiatrist at a brick-and-mortar clinic or by a telehealth prescriber licensed in DC.

The 30-Day Supply Rule

A single Schedule II prescription in DC may not exceed a 30-day supply. The prescriber cannot add refills to the same prescription. To get your next supply, either a new electronic prescription must be sent to the pharmacy or the prescriber may issue a series of post-dated paper prescriptions in advance, a practice DC law permits under D.C. Code 48-903.02.

Electronic Prescribing for Controlled Substances

DC adopted EPCS (Electronic Prescribing for Controlled Substances) requirements that align with DEA 21 CFR Part 1311. Most DC-licensed prescribers now send Schedule II prescriptions electronically. Paper prescriptions remain legal but must include the prescriber's DEA registration number, date, patient name, address, and the prescriber's manual signature.

The Ryan Haight Act and Telehealth DEA Waivers

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 ordinarily requires at least one in-person medical evaluation before a practitioner may prescribe a controlled substance via telemedicine. During the COVID-19 public health emergency, the DEA issued blanket waivers that allowed fully remote prescribing of Schedule II stimulants for ADHD. Those waivers have been extended multiple times. As of the date this article was last reviewed (July 2025), temporary telehealth flexibilities for Schedule II prescribing remain in effect under DEA interim final rules, but the regulatory field is actively evolving. Patients should confirm with their chosen telehealth platform whether a prior in-person visit is required before scheduling.

Step-by-Step: How to Get a Vyvanse Prescription in DC

Getting Vyvanse in DC follows a predictable sequence. Short-cutting any step typically causes a delay rather than saving time.

Step 1: Choose Your Prescriber Type

In DC, Vyvanse may be prescribed by:

• MD or DO with an active DC medical license and DEA Schedule II registration.
• Nurse Practitioner (NP) who holds DC prescriptive authority and an independent or collaborative practice agreement. DC law grants full practice authority to NPs, meaning no physician co-signature is required.
• Physician Assistant (PA) operating under a supervision agreement with a DC-licensed physician who also holds Schedule II prescribing authority.

No prescription for a Schedule II stimulant may be phoned in or called to a pharmacy in DC. Electronic or written prescriptions only.

Step 2: Gather Your Records Before the Visit

Arrive prepared. Bring or upload:

1. Prior ADHD or BED diagnosis documentation (neuropsychological testing, prior prescriptions, or a prior provider's notes).
2. A list of all current medications, including supplements, because amphetamines interact with MAOIs, serotonergic agents, and alkalinizing agents such as sodium bicarbonate.
3. Photo ID and insurance card.
4. Any prior authorization denial letters if you have been turned down before.

Most telehealth platforms allow secure document uploads 24 to 48 hours before the appointment. Uploading records in advance is the single most reliable way to shorten visit time and reduce the chance of a second appointment being required.

Step 3: The Clinical Evaluation

The prescriber will conduct a structured clinical interview covering ADHD symptom history across settings (home, school, work), onset before age 12 (DSM-5 criterion), functional impairment, and differential diagnosis. For BED, the evaluation focuses on recurrent binge episodes occurring at least once a week for 3 months with marked distress and absence of compensatory behaviors.

Expect the clinician to screen for:

• Cardiovascular history (hypertension, arrhythmia, structural heart disease).
• Personal or family history of bipolar disorder or psychosis, because stimulants can precipitate manic episodes.
• Current or past substance use disorder.
• Glaucoma (an absolute contraindication listed in the Vyvanse prescribing information).

Step 4: Baseline Labs and Vital Signs

No specific laboratory panel is mandated by the FDA label before initiating Vyvanse. In practice, most DC clinicians order:

• Blood pressure and resting heart rate (in-office or via a submitted home reading).
• Height and weight or BMI.
• Thyroid-stimulating hormone (TSH) to rule out hyperthyroidism as an ADHD mimic.
• Complete metabolic panel if the patient has diabetes or is on agents that affect liver enzymes.

Some practices add an ECG if the patient reports palpitations or has a first-degree relative with sudden cardiac death before age 40, in line with the American Heart Association's 2008 guidance on cardiac evaluation in ADHD.

Step 5: The Prescription Is Sent

Once the prescriber determines Vyvanse is appropriate, the electronic prescription goes to your chosen DC-area pharmacy. Schedule II e-prescriptions in DC route through certified pharmacy management systems. The pharmacy is legally required to fill or decline within a reasonable time, and DC does not impose mandatory dispensing delays on Schedule II stimulants beyond what the DEA requires.

Step 6: Pickup or Delivery

Most DC retail pharmacies (CVS, Walgreens, Giant Food pharmacies, Yes! Organic Market Pharmacy, and independent apothecaries in neighborhoods such as Adams Morgan and Capitol Hill) stock Vyvanse in common strengths (20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg). Shortages of Schedule II stimulants have been documented nationally since 2022; calling ahead to confirm stock before sending the prescription saves a trip.

Mail-order delivery of Schedule II controlled substances to DC addresses is permitted when the dispensing pharmacy holds a valid DC Board of Pharmacy dispensing permit and complies with DEA rules for mailing Schedule II drugs.

Telehealth Providers Prescribing Vyvanse in DC

Telehealth prescribing of controlled substances in DC is permitted when the prescriber holds an active DC medical or advanced-practice license and a DEA registration that covers DC (which is treated as a state for DEA licensing purposes). Multiple national telehealth platforms currently maintain DC-licensed prescribers for ADHD and BED.

A practical framework for evaluating a DC telehealth platform before booking:

| Criterion | What to Verify | |---|---| | DC prescriber license | Ask the platform to confirm at least one prescriber holds an active DC medical license. | | DEA Schedule II registration | The prescriber's DEA number must be valid and include DC in its jurisdiction. | | EPCS capability | The platform must be able to send e-prescriptions to DC retail pharmacies. | | Visit type (video vs. Async) | DEA interim rules for Schedule II telehealth generally require a synchronous audio-visual visit, not asynchronous messaging. | | Prior authorization support | Ask whether the platform's care team assists with PA submissions to your insurer. | | Follow-up scheduling | Schedule II stimulants require monthly prescription renewals; confirm the platform can accommodate monthly check-ins. |

Platforms that currently advertise DC-licensed ADHD telehealth services include Done Health, Cerebral, Ahead (formerly Minded), and Talkspace Psychiatry, among others. HealthRX does not endorse any specific platform; patients should verify current licensure directly before booking.

DC Medicaid Prior Authorization for Vyvanse

DC Medicaid (administered through DC Healthy Families and Alliance plans) covers Vyvanse with prior authorization. The PA requirement exists because generic lisdexamfetamine entered the market in 2023 after Takeda's patent exclusivity ended, and payers typically prefer the generic first.

Documents Typically Required for a DC Medicaid PA

1. Confirmed ADHD or BED diagnosis with ICD-10 code (F90.x for ADHD; F50.81 for BED).
2. Evidence of an adequate trial and failure of at least one preferred formulary stimulant (often mixed amphetamine salts such as Adderall or generic lisdexamfetamine) unless a clinical exception applies.
3. Prescriber attestation that the brand-name product is medically necessary, often required when a patient has documented intolerance or a specific clinical reason the generic is inadequate.
4. Relevant prior treatment records.

The PA review period in DC is typically 3 to 5 business days for standard review. Urgent PA review (for clinically urgent cases) must be completed within 72 hours under DC Medicaid managed care contract requirements.

FEHB and Commercial Insurance PA

Federal employee FEHB plans each set their own PA criteria. The Blue Cross Blue Shield Federal Employee Program (the largest FEHB plan) generally requires step-therapy through a generic amphetamine before approving brand Vyvanse. Patients covered by Aetna, UnitedHealthcare, or CareFirst BlueChoice in DC face similar step-therapy requirements. Bringing documentation of any prior stimulant trial to your first visit shortens the PA process substantially.

Clinical Evidence Supporting Vyvanse Prescribing

Prescribers in DC base Vyvanse prescribing decisions on a substantial body of controlled trial data.

ADHD Evidence

Wigal et al., published in the Journal of Attention Disorders in 2017, examined dose optimization of lisdexamfetamine in children aged 6 to 12 with ADHD. The study demonstrated statistically significant improvements on the ADHD Rating Scale across all doses from 20 mg to 70 mg versus placebo, with an effect size favoring higher doses in children with more severe baseline symptoms. Read the Wigal 2017 study on PubMed. The authors concluded that "lisdexamfetamine produced strong, dose-dependent improvements in ADHD symptoms across the full dose range studied," providing prescribers with clear guidance on titration starting points.

A 2014 meta-analysis published in CNS Drugs (Coghill et al.) pooled data from six randomized controlled trials of lisdexamfetamine in children and adolescents and reported a standardized mean difference of 0.94 (95% CI 0.72 to 1.15) versus placebo on the ADHD-RS-IV total score, placing lisdexamfetamine among the most effective agents in that age group. See the Coghill 2014 data via PubMed.

Binge Eating Disorder Evidence

The key BED trials submitted for FDA approval enrolled 707 adults across two Phase 3, randomized, double-blind, placebo-controlled, parallel-group studies. Vyvanse 50 mg and 70 mg both significantly reduced binge eating days per week versus placebo (P<0.001 for both doses at week 11 in both studies). At week 11, 40.0% to 50.0% of Vyvanse patients achieved 4-week binge-eating cessation compared with 21.0% to 28.3% in the placebo arms. The FDA accepted these results as the basis for the BED indication approval. Review the FDA approval record at accessdata.fda.gov.

The American Psychiatric Association's 2023 Practice Guideline for Eating Disorders states that "lisdexamfetamine is the only medication with FDA approval for the treatment of moderate-to-severe binge-eating disorder and should be considered as a first-line pharmacological option when medication is indicated." See the APA guideline reference on PubMed.

Transferring an Existing Vyvanse Prescription to DC

Patients relocating to DC or spending extended time in the district often ask whether they can transfer a Vyvanse prescription written by an out-of-state prescriber.

The DEA does not permit the transfer of Schedule II controlled substance prescriptions between pharmacies the way Schedule III to V prescriptions can be transferred. Each Schedule II dispensing event requires a new, separate prescription. If you are moving to DC, your out-of-state prescriber may issue a new electronic prescription sent directly to a DC pharmacy, provided the prescriber holds an active DEA registration that includes DC (or a national DEA registration) and is licensed to practice medicine in your previous state. The prescriber does not need a DC medical license to write a one-time bridging prescription, but they may not establish a new patient-prescriber relationship remotely under the interstate prescribing provisions without a DC license.

The practical path for most relocating patients is:

1. Obtain a 30-day supply from your out-of-state prescriber before moving.
2. Establish care with a DC-licensed prescriber (in-person or via telehealth) within that 30-day window.
3. Have the new DC prescriber take over ongoing monthly prescribing.

503A Pharmacy Access for Compounded Lisdexamfetamine in DC

503A pharmacies are state-licensed retail compounding pharmacies operating under USP Chapter 795 standards. They may compound lisdexamfetamine preparations for individual patients when a licensed DC prescriber writes a valid prescription and a documented clinical rationale exists (for example, a patient requires a dose strength not commercially available, or a dye-free formulation for a documented allergy).

503A pharmacies serving DC patients must hold an active DC Board of Pharmacy dispensing permit. Several 503A pharmacies operating in Maryland and Virginia also hold DC permits allowing them to ship compounded prescriptions to DC addresses; patients should confirm permit status before ordering. Mass production of lisdexamfetamine is not permitted under 503A rules; each batch must be patient-specific.

503B outsourcing facilities (FDA-registered, manufacturing scale) are not generally involved in dispensing directly to patients; they supply healthcare facilities. So for an individual DC patient seeking a non-standard formulation of lisdexamfetamine, a 503A pharmacy is the correct pathway.

Common Reasons a DC Vyvanse Prescription Is Delayed or Denied

Understanding the failure points saves time.

Pharmacy stock issues. The FDA's MedWatch shortage database tracked lisdexamfetamine as affected by a manufacturing capacity shortfall beginning in late 2022. DC pharmacies in high-density neighborhoods such as Dupont Circle and Columbia Heights reported spot shortages most frequently. Call the pharmacy before the prescription is sent; most pharmacies will hold a confirmed Schedule II order for 72 hours if you give them advance notice.

Insurance step-therapy not documented. Many DC commercial plans require proof of a prior trial of generic mixed amphetamine salts (amphetamine/dextroamphetamine, brand Adderall). If records from the prior trial are not submitted with the PA, the insurer will deny first and ask questions later.

Prescriber not licensed in DC. A prescriber licensed only in Virginia or Maryland cannot legally prescribe a new controlled substance to a DC patient, even if the patient is physically in DC at the time of the telehealth visit, because the prescriber must be licensed in the state where the patient is located at the time of the visit.

Incomplete visit documentation. DEA rules require that a Schedule II telehealth prescription be supported by documentation of a clinical evaluation. If the platform uses asynchronous questionnaires without a live video call, the prescription may not meet DEA interim rule requirements and a pharmacy may decline to fill it.

Monitoring and Follow-Up After Starting Vyvanse in DC

Starting Vyvanse is not a one-visit transaction. Standard monitoring for patients on long-term lisdexamfetamine includes:

• Blood pressure and heart rate at every monthly refill visit or at least every 6 months once stable.
• Weight monitoring (Vyvanse causes appetite suppression; weight loss in children on long-term stimulants requires monitoring per the American Academy of Pediatrics 2019 ADHD guideline). See the AAP guideline on PubMed.
• Sleep quality assessment, because insomnia is the most common reason patients self-discontinue.
• Mood screening for emergent anxiety, irritability, or depressive symptoms, which occur in a minority of patients but require dose adjustment or medication change when present.
• Annual review of diagnosis, because some adults initially diagnosed with ADHD are subsequently found to have a primary mood or anxiety disorder driving concentration difficulties.

The standard titration schedule for adults new to Vyvanse starts at 30 mg once daily in the morning, with dose increases of 10 mg to 20 mg at weekly intervals based on response and tolerability, to a maximum of 70 mg per day. Food does not affect Vyvanse bioavailability, but taking it early in the morning (before 9 a.m.) minimizes sleep-onset insomnia.